HCPCS Code J1442: Filgrastim (G-CSF) billing guide

Key Takeaways

HCPCS Code J1442 describes an injection of filgrastim (G-CSF), excluding biosimilars, billed per 1 microgram – it covers Neupogen (Amgen) only, not biosimilar products

Medicare reimburses J1442 at ASP+6% in physician office settings under Part B; hospital outpatient billing follows APC grouping rules instead

Biosimilar filgrastim products have separate HCPCS codes – using J1442 for a biosimilar like tbo-filgrastim is a claim error that triggers denials

Pabau’s practice management software keeps administration records, NDC data, and diagnosis codes in one patient file, so billing staff aren’t chasing down documentation before a claim goes out

HCPCS Code J1442 is the Level II code for injection of filgrastim (granulocyte colony-stimulating factor, G-CSF), excluding biosimilars, billed per 1 microgram. It applies only to Neupogen, the originator biologic; every FDA-approved filgrastim biosimilar carries its own separate J-code.

That split causes the most common denial reason for this code: billing the originator code for a biosimilar product, or vice versa, especially in practices that stock multiple filgrastim products or switch between them mid-cycle.

This reference covers the unit calculation, place-of-service differences, NDC crosswalk, ICD-10 pairings, and the biosimilar code landscape coders need to navigate in 2026.

HCPCS Code J1442: definition and official descriptor

HCPCS Code J1442 is the Level II code for injection of filgrastim (granulocyte colony-stimulating factor), excluding biosimilars, billed per 1 microgram. The code applies exclusively to Neupogen, the originator biologic manufactured by Amgen. Any filgrastim product that has received FDA biosimilar designation is billed under a separate HCPCS J-code, not J1442.

The “per 1 microgram” unit structure is critical. Unlike flat-dose codes, J1442 requires the biller to calculate the exact number of micrograms administered and bill that many units. A 300 mcg dose = 300 units of J1442. Rounding to the nearest vial size without confirming the administered dose is a documentation error that auditors flag consistently.

Confirming code status annually matters. CMS issues HCPCS updates each January, and code descriptors or coverage policies can shift. The CMS HCPCS overview page is the authoritative source for the current code file. Practices relying on cached references from prior years risk billing under superseded descriptors.

Clinical indications that support medical necessity

Medicare and commercial payers require medical necessity documentation tied to an approved clinical indication. Filing J1442 without a matching ICD-10 diagnosis code linked to a covered indication is the fastest path to a medical necessity denial. The four primary indications for filgrastim billing are:

• Chemotherapy-induced neutropenia (CIN): the most common billing context; filgrastim stimulates neutrophil recovery after myelosuppressive chemotherapy regimens
• Febrile neutropenia prophylaxis: administered prophylactically in patients at high risk of febrile neutropenia based on regimen and patient factors
• Bone marrow transplant (BMT) support: accelerates neutrophil engraftment following myeloablative conditioning
• Peripheral blood stem cell (PBSC) mobilization: used to mobilize CD34+ progenitor cells prior to collection for autologous transplant
• Severe chronic neutropenia (SCN): congenital, cyclic, or idiopathic neutropenia with documented ANC thresholds per FDA label

Off-label indications are not reliably reimbursable under Medicare. If a payer’s local coverage determination (LCD) or national coverage determination (NCD) does not list the clinical scenario, expect a denial regardless of clinical rationale. Always verify coverage against the active LCD from the relevant Medicare Administrative Contractor (MAC) before submitting.

Practice management software like Pabau keeps the diagnosis, physician order, and administration note attached to the same patient record, so billing staff can confirm indication coverage before the claim leaves the practice.

Medicare reimbursement for HCPCS Code J1442

Medicare Part B reimburses J1442 under the Average Sales Price (ASP) methodology. The formula is ASP+6% for physician office and practice settings. CMS publishes updated ASP pricing quarterly, so the per-unit reimbursement amount shifts four times per year. Dollar figures cited in static references go stale quickly.

The CMS fee schedule tool provides current payment amounts by HCPCS code and geographic locality. Use it before quoting rates to patients or setting internal benchmarks.

Hospital outpatient billing deserves a separate note. When a patient receives filgrastim at a hospital outpatient department, the facility claim goes through the Outpatient Prospective Payment System (OPPS).

The drug cost is grouped into an Ambulatory Payment Classification (APC), not paid separately at ASP+6%. Physician practices billing for the professional component in that setting need to confirm which cost elements each party can claim.

Misunderstanding the OPPS model is a common source of overpayment findings in oncology practices. Reliable practice management software that tracks claim type by place of service helps flag these scenarios before submission.

J1442 billing guidelines: units, modifiers, and common errors

The unit calculation is where most J1442 errors originate. Billers who default to “1 unit per injection” are understating the claim. Billers who round up to the full vial even when a partial dose was used are overclaiming. Both are audit risks.

Calculating billable units

Bill the number of micrograms actually administered, not the vial size. Neupogen is available in 300 mcg/1 mL and 480 mcg/1.6 mL vials (both at a 300 mcg/mL concentration). If the physician orders 300 mcg and administers the full vial, bill 300 units of J1442.

If 480 mcg is ordered and the full vial used, bill 480 units. Document the administered dose, vial strength, and any waste in the administration record to support the unit count.

Administration codes to pair with J1442

In physician office settings, J1442 covers the drug cost only. The injection administration requires a separate CPT code. Subcutaneous injection pairs with CPT 96372 (therapeutic, prophylactic, or diagnostic injection, subcutaneous or intramuscular). Do not report J1442 alone when the drug is administered in-office.

The claim will miss the professional work component. Confirm payer-specific bundling rules, as some commercial plans package administration differently. Accurate medical forms and documentation tied to each administration encounter reduce discrepancies between the clinical record and the claim.

Common J1442 billing errors

• Billing J1442 for a biosimilar product – the single most frequent denial reason; each biosimilar has its own HCPCS code
• Incorrect unit count – billing 1 unit instead of the mcg administered; or billing full vial when partial dose given
• Missing NDC crosswalk – many payers require the NDC on the claim line alongside J1442; omission triggers edits
• No administration code – submitting the drug J-code without a paired CPT administration code in office settings
• Mismatched diagnosis code – linking J1442 to a diagnosis that does not support medical necessity per the applicable LCD
• Wrong place of service – billing POS 11 rules when the drug was administered in a hospital outpatient department

The AAPC HCPCS code lookup provides coding guidance notes and crosswalk data that help billers confirm modifier requirements before submission. The same pre-submission checklist approach applies to other single-ingredient J-codes, such as HCPCS Code J3420 for vitamin B-12 injections, and catches most of these errors before the claim reaches the payer. Pabau’s EHR integration workflow connects administration records directly to the billing record, reducing manual transcription errors between the clinical and billing sides.

Documentation requirements for J1442 claims

Every J1442 claim needs a paper trail that connects the drug to the patient encounter, the clinical indication, and the administered dose. Missing any one of these links gives a payer a clean basis for denial on medical necessity or documentation grounds. Below is the minimum documentation set practices should maintain.

• Physician order or prescription: dated, signed, specifying drug, dose, route, and frequency
• Diagnosis supporting medical necessity: ICD-10 code documented in the encounter note and linked to the claim
• Administration record: date, time, drug name (Neupogen, not generic “filgrastim”), NDC, lot number, dose administered, and route
• Lab results (for neutropenia indications): ANC count confirming neutropenia or prophylaxis threshold, particularly for SCN and CIN claims
• Prior authorization documentation (if applicable): payer approval reference number, approval dates, authorized quantity
• Waste documentation: if a partial vial was used, document the amount wasted per payer requirements for partial-vial billing

Oncology practices with high J1442 volume benefit from standardized templates that capture all required fields at the point of care, rather than reconstructing documentation at billing time. Linking prescription management software to the clinical record ensures the drug order, NDC, and administered dose flow into the billing record without manual re-entry.

This matters for HIPAA-compliant record-keeping as much as for billing accuracy: HIPAA compliance guide requires that drug administration records be accessible, accurate, and tied to the patient encounter.

Keep injectable drug documentation and billing records in one place

Pabau keeps drug administration records, NDC data, and diagnosis codes attached to the same patient file – so your billing team spends less time chasing documentation and more time on clean submissions.

Book a demo

J1442 vs biosimilar filgrastim codes: what coders need to know

The FDA has approved multiple filgrastim biosimilars, each assigned its own HCPCS J-code. Using J1442 for any of these products is a coding error. The distinction matters for claim accuracy, but also for drug cost transparency: CMS tracks originator vs biosimilar utilization specifically, and payers increasingly steer toward lower-cost biosimilars through formulary policy and prior authorization, much as it does with oncology imaging agents like the radiolabeled antibody code.

Verify the current biosimilar code list against the CMS HCPCS annual release before each plan year. The biosimilar landscape continues to evolve as new FDA approvals generate new HCPCS codes. Using a stale code crosswalk for a biosimilar that has received a new code is an accuracy problem that appears in any payer audit of J-code claims.

The PGM HCPCS lookup tool pulls live CMS data and is a useful secondary check on current code assignments.

Practices that manage both Neupogen and biosimilar products in the same formulary should maintain a product-to-code mapping reference at the point of care. When the administering nurse or pharmacist documents the specific product name and NDC, that detail propagates to billing and eliminates the ambiguity about which J-code applies.

This is exactly where integrated paperless record-keeping removes a human error point: the NDC recorded in the administration note is the NDC that flows into the J-code crosswalk, not what a biller guesses from the drug order alone.

NDC-to-HCPCS crosswalk for J1442

Most payers require the National Drug Code (NDC) on the claim line alongside J1442. The NDC identifies the exact product, strength, and manufacturer, giving payers the detail they need to verify the J-code assignment. Neupogen is available in two vial formats, each with its own NDC.

NDC numbers are subject to manufacturer lot and packaging changes. Always pull the NDC from the vial label at time of administration rather than from a static internal reference. The on-claim NDC format required by most payers is the 11-digit format with leading zeros (labeler-product-package: 5-4-2 segments). Confirm format requirements with each commercial payer before submitting.

Robust digital documentation forms that capture NDC at the point of administration eliminate the re-entry step entirely. For broader guidance on managing patient data trails securely, patient data security tools support the access controls and audit logging required when drug administration records are accessed for billing purposes.

ICD-10 codes that support J1442 medical necessity

CMS and commercial payers evaluate J1442 medical necessity against the paired diagnosis code. The diagnosis must reflect a condition for which filgrastim has an established, payer-recognized indication. Other immunosuppressive biologics, like HCPCS Code J0129 for abatacept, carry the same requirement for a matching, LCD-approved diagnosis. Filing J1442 against a diagnosis that does not appear in the payer’s LCD or coverage policy results in a medical necessity denial, even when the clinical rationale is sound.

Sequencing matters. For CIN, D70.1 as the principal diagnosis is appropriate when the encounter is specifically for neutropenia management. When the patient is receiving chemotherapy on the same day, Z51.11 often serves as principal with D70.1 as secondary, depending on the reason for the encounter. Your MAC’s LCD for colony-stimulating factors will specify approved diagnoses and any required sequencing.

Cross-reference your ICD-10 diagnostic codes against the active LCD before finalizing claims. For practices managing oncology and related specialties, time-saving practice features like automated diagnosis-to-procedure linkage checks reduce the chance of a medical necessity mismatch reaching the payer.

Place of service and setting-specific billing for J1442

Where the drug is administered determines which billing rules apply. This is one of the most frequently misunderstood aspects of J1442 billing in oncology and infusion practices, particularly those with both in-office infusion capabilities and hospital outpatient affiliation agreements.

Physician office (POS 11)

The practice bills J1442 directly on the professional claim (CMS-1500 / 837P). Drug reimbursement is ASP+6% under the Part B drug payment policy. CPT 96372 is added for the subcutaneous injection. Whether it’s an oncology group or general practice, the practice owns the drug cost exposure: it purchases Neupogen, administers it, and receives the ASP+6% reimbursement.

Practices need to track drug acquisition costs against reimbursement rates to monitor margin on buy-and-bill arrangements.

Hospital outpatient department (POS 22)

The facility submits an institutional claim (UB-04 / 837I) under OPPS. J1442 is included in the encounter, but payment is packaged into the relevant APC rather than paid separately at ASP+6%.

A physician who sees the patient in a provider-based outpatient department may bill a separate professional claim for the E&M or supervision component, but cannot separately bill J1442 on a professional claim for the same encounter if the facility is billing for the drug under OPPS.

This split-billing confusion is a common compliance risk. Keeping detailed practice management records of which services were rendered in which setting prevents inadvertent double-billing.

Ambulatory surgical center (ASC)

Filgrastim is not typically a covered Part B drug in the ASC setting for most indications, as ASC payment is structured around surgical procedures. Confirm with the relevant payer before billing J1442 from an ASC facility.

Most filgrastim administration in ASC settings occurs incidentally to a listed procedure, in which case the drug cost is often considered packaged into the procedure payment.

Conclusion

HCPCS Code J1442 claims fail most often because of two avoidable errors: wrong product code (using J1442 for a biosimilar) and wrong unit count (billing vial size instead of administered dose). Both happen when the clinical administration record and the billing record are not connected.

When those two records are connected in real time, the most common J1442 denial reasons disappear before the claim is submitted.

Pabau keeps drug administration documentation, NDC data, and diagnosis codes attached to the same patient record, so billing staff pull that detail straight from the clinical record instead of re-entering it. To see how that workflow fits an oncology or infusion practice, book a demo and walk through the J-code billing workflow with the team.

Continue your research

Need a framework for managing injectable drug documentation? Medical forms at your healthcare practice covers how structured intake and administration forms reduce billing errors across drug infusion workflows.

Want to understand how billing integrates with clinical records? EHR integration workflow explains how connecting clinical and billing systems reduces manual data re-entry and claim errors.

Running a multi-location oncology or infusion practice? Multi-location practice management covers how to standardize billing protocols and drug administration documentation across sites.

Frequently asked questions